« Back to News

McKesson and US Oncology Research Announce Schedule of Presentations at the 2017 American Society of Hematology Annual Meeting and Exposition

19 abstracts on clinical research conducted by top affiliated investigators are scheduled for presentation

The Woodlands, Texas (December 4, 2017) – At the 59th American Society of Hematology Annual Meeting and Exposition (ASH), leading investigators from The US Oncology Network and US Oncology Research will showcase detailed findings from 19 studies (four orals, 14 poster presentations and one e-publication) covering topics such as multiple myeloma, chronic lymphocytic leukemia, myeloproliferative neoplasms and more. The 59th ASH Annual Meeting, a premier scientific event in malignant and non-malignant hematology, will be held December 9-12 in Atlanta.

“The research and breakthroughs in oncology and hematology coming from community oncologists are significantly advancing treatment options for cancer,” said Michael Seiden, MD, PhD, chief medical officer for The US Oncology Network and US Oncology Research. “The commitment to current and future patients from these physicians is astounding. We are proud to take part in this important meeting, and I’m looking forward to this year’s presentations at ASH.”

Habte Yimer, MD, medical oncologist and hematologist with Texas Oncology, a practice in The US Oncology Network, co-authored a study being presented on chronic lymphocytic leukemia titled, “Improvements in Health-Related Quality of Life and Symptoms in Patients with Previously Untreated Chronic Lymphocytic Leukemia: Results from the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine.” The oral presentation will take place Monday, December 11 at 11:30am ET in Bldg. C, Lvl. 2, C208-C210 (Georgia World Congress Center).

“In previous reporting of the results in June of 2017, we have shown the Obinutuzumab/Bendamustine combination to be safe and has significant activity in first-line setting,” said Dr. Yimer. “We will see if those results translate into clinically meaningful improvement in health-related quality of life in this year’s ASH presentation.”

Additionally, Dr. Yimer will present “Results of an Interim Safety Analysis of a Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) in Previously Untreated and Relapsed Patients (Pts) with Multiple Myeloma (MM).” The poster abstract will be available Saturday, December 9 from 5:30-7:30pm ET in Bldg. A, Lvl. 1, Hall A2.

The full schedule of US Oncology Research affiliated data presentations, including location and author information, can be found here. For more information or to interview a trial investigator, contact Claire Crye at 281-825-9927 or or Kerry Sinclair at 323-602-1096 or

About US Oncology Research
US Oncology Research draws from a network of experienced investigators and dedicated clinical staff who specialize in oncology clinical trials. US Oncology Research serves approximately 60 research sites and more than 165 locations managing about 300 active trials at any given time. Physicians in the research network have enrolled more than 70,000 patients in over 1,500 trials since inception about two decades ago and have played a role in more than 70 FDA-approved cancer therapies, approximately one-third of all cancer therapies approved by the FDA to date. For more information visit

About The US Oncology Network
Every day, The US Oncology Network helps more than 1,400 independent physicians deliver value-based, integrated care for patients — close to home. Through The Network, these independent doctors come together to form a community of shared expertise and resources dedicated to advancing local cancer care and to delivering better patient outcomes. The Network provides doctors with access to coordinated resources, best business practices, and the experience, infrastructure and support of McKesson. This collaboration allows the doctors in The Network to focus on the health of their patients, while McKesson focuses on the health of their practices. Together, The Network and its affiliated physicians are committed to the success of independent practices, everywhere. For more information, visit

About McKesson
McKesson Corporation, currently ranked 6th on the FORTUNE 500, is a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology. McKesson partners with pharmaceutical manufacturers, providers, pharmacies, governments and other organizations in healthcare to help provide the right medicines, medical products and healthcare services to the right patients at the right time, safely and cost-effectively. United by our ICARE shared principles, our employees work every day to innovate and deliver opportunities that make our customers and partners more successful — all for the better health of patients. McKesson has been named the “Most Admired Company” in the healthcare wholesaler category by FORTUNE, a “Best Place to Work” by the Human Rights Campaign Foundation, and a top military-friendly company by Military Friendly. For more information, visit

Media Contact
Claire Crye